JP2020533276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533276A5 JP2020533276A5 JP2020505478A JP2020505478A JP2020533276A5 JP 2020533276 A5 JP2020533276 A5 JP 2020533276A5 JP 2020505478 A JP2020505478 A JP 2020505478A JP 2020505478 A JP2020505478 A JP 2020505478A JP 2020533276 A5 JP2020533276 A5 JP 2020533276A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- raav vector
- nucleic acid
- aav
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540053P | 2017-08-01 | 2017-08-01 | |
| US62/540,053 | 2017-08-01 | ||
| US201762583890P | 2017-11-09 | 2017-11-09 | |
| US62/583,890 | 2017-11-09 | ||
| US201762596535P | 2017-12-08 | 2017-12-08 | |
| US201762596670P | 2017-12-08 | 2017-12-08 | |
| US62/596,535 | 2017-12-08 | ||
| US62/596,670 | 2017-12-08 | ||
| PCT/US2018/044892 WO2019028192A1 (en) | 2017-08-01 | 2018-08-01 | METHODS OF GENE THERAPY TARGETING FACTOR VIII (FVIII) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533276A JP2020533276A (ja) | 2020-11-19 |
| JP2020533276A5 true JP2020533276A5 (enExample) | 2021-11-25 |
| JP7499174B2 JP7499174B2 (ja) | 2024-06-13 |
Family
ID=65234171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505478A Active JP7499174B2 (ja) | 2017-08-01 | 2018-08-01 | 第ｖｉｉｉ因子（ｆｖｉｉｉ）遺伝子治療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200237930A1 (enExample) |
| EP (1) | EP3661541A4 (enExample) |
| JP (1) | JP7499174B2 (enExample) |
| KR (2) | KR20200066289A (enExample) |
| CN (1) | CN111163796A (enExample) |
| AU (2) | AU2018312565A1 (enExample) |
| BR (1) | BR112020001979A2 (enExample) |
| CA (1) | CA3071519A1 (enExample) |
| CL (1) | CL2020000295A1 (enExample) |
| CO (1) | CO2020002283A2 (enExample) |
| IL (1) | IL272373A (enExample) |
| MX (1) | MX2020001402A (enExample) |
| MY (1) | MY208862A (enExample) |
| PE (1) | PE20200722A1 (enExample) |
| PH (1) | PH12020500239A1 (enExample) |
| SG (1) | SG11202000650YA (enExample) |
| WO (1) | WO2019028192A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| AU2019205942B2 (en) | 2018-01-05 | 2025-05-15 | Platelet Biogenesis, Inc. | Compositions and methods for producing megakaryocytes |
| US12403161B2 (en) | 2018-06-29 | 2025-09-02 | Stellular Bio, Inc. | Compositions for drug delivery and methods of use thereof |
| JP7684212B2 (ja) * | 2018-08-03 | 2025-05-27 | サンガモ セラピューティクス， インコーポレイテッド | 第ｖｉｉｉ因子の発現による改善された臨床パラメーター |
| WO2020168362A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
| JP7795357B2 (ja) | 2019-03-13 | 2026-01-07 | ジェネレーション バイオ カンパニー | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| CN110684798A (zh) * | 2019-09-03 | 2020-01-14 | 深圳新诺微环生物科技有限公司 | 肌肉靶向的微环dna基因治疗 |
| US20220396610A1 (en) * | 2019-11-01 | 2022-12-15 | Freeline Therapeutics Limited | Factor viii polypeptide |
| EP4069269A4 (en) * | 2019-12-06 | 2023-12-27 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION |
| CN114989307B (zh) * | 2022-05-11 | 2023-08-01 | 华兰生物工程股份有限公司 | 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法 |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818439B1 (en) * | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| WO2001027303A1 (en) * | 1999-10-12 | 2001-04-19 | The University Of North Carolina At Chapel Hill | Adeno-associated virus vectors encoding factor viii and methods of using the same |
| ES2813698T3 (es) * | 2013-09-12 | 2021-03-24 | Biomarin Pharm Inc | Vectores de AAV que comprenden un gen que codifica el factor VIII |
| AU2015301598B2 (en) * | 2014-08-13 | 2020-07-16 | Liron Elkouby | An improved expression cassette for packaging and expression of variant Factor VIII for the treatment of hemostasis disorders |
| EP3626274B1 (en) * | 2015-04-16 | 2025-01-22 | Emory University | Recombinant promoters and vectors for protein expression in liver and use thereof |
| BR112018006074A2 (pt) * | 2015-09-24 | 2018-10-09 | Biomarin Pharm Inc | vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas |
| KR102766526B1 (ko) * | 2015-10-28 | 2025-02-13 | 상가모 테라퓨틱스, 인코포레이티드 | 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법 |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| US20190144524A1 (en) * | 2016-01-14 | 2019-05-16 | The Children's Hospital Of Philadelphia | Factor viii variants, nucleic acid sequences, and methods and uses for treatment of hemostasis disorders |
-
2018
- 2018-08-01 BR BR112020001979-8A patent/BR112020001979A2/pt unknown
- 2018-08-01 AU AU2018312565A patent/AU2018312565A1/en not_active Abandoned
- 2018-08-01 SG SG11202000650YA patent/SG11202000650YA/en unknown
- 2018-08-01 CN CN201880064058.9A patent/CN111163796A/zh active Pending
- 2018-08-01 US US16/635,957 patent/US20200237930A1/en not_active Abandoned
- 2018-08-01 JP JP2020505478A patent/JP7499174B2/ja active Active
- 2018-08-01 EP EP18840279.6A patent/EP3661541A4/en active Pending
- 2018-08-01 MY MYPI2020000557A patent/MY208862A/en unknown
- 2018-08-01 KR KR1020207005859A patent/KR20200066289A/ko not_active Ceased
- 2018-08-01 WO PCT/US2018/044892 patent/WO2019028192A1/en not_active Ceased
- 2018-08-01 PE PE2020000180A patent/PE20200722A1/es unknown
- 2018-08-01 MX MX2020001402A patent/MX2020001402A/es unknown
- 2018-08-01 KR KR1020247034886A patent/KR20240160648A/ko active Pending
- 2018-08-01 CA CA3071519A patent/CA3071519A1/en active Pending
-
2020
- 2020-01-30 IL IL272373A patent/IL272373A/en unknown
- 2020-01-31 CL CL2020000295A patent/CL2020000295A1/es unknown
- 2020-01-31 PH PH12020500239A patent/PH12020500239A1/en unknown
- 2020-02-28 CO CONC2020/0002283A patent/CO2020002283A2/es unknown
-
2024
- 2024-09-03 AU AU2024219336A patent/AU2024219336A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533276A5 (enExample) | ||
| RU2018119710A (ru) | Кодирующие фактор viii варианты с пониженным содержанием cpg, композиции и способы, и применение в лечении нарушений гемостаза | |
| JP2021003120A5 (enExample) | ||
| JP7493566B2 (ja) | 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達 | |
| JP2019503649A5 (enExample) | ||
| JP2024009857A5 (enExample) | ||
| JP2021087431A5 (enExample) | ||
| JP2019116492A5 (enExample) | ||
| JP2018506261A5 (enExample) | ||
| JP2021106619A5 (enExample) | ||
| JP2018522529A5 (enExample) | ||
| TW201840850A (zh) | 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症 | |
| JP2020522269A5 (enExample) | ||
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP2018531609A5 (enExample) | ||
| US20210198692A1 (en) | Adeno-associated viral vector-mediated gene therapy for treating fragile x-associated disorders | |
| US20040002159A1 (en) | Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof | |
| JP2017529395A5 (enExample) | ||
| JPWO2020041773A5 (enExample) | ||
| JPWO2020186207A5 (enExample) | ||
| JPWO2020186150A5 (enExample) | ||
| RU2020108209A (ru) | Способы генотерапии с использованием гена фактора viii (fviii) | |
| NZ741860B2 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| JPWO2021195218A5 (enExample) | ||
| RU2022111695A (ru) | Выделенная нуклеиновая кислота, которая кодирует слитый белок на основе FVIII-BDD и гетерологичного сигнального пептида, и ее применение |